Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Shares of Axsome Therapeutics Are Down Friday


Friday continued what has been a bad week for Axsome Therapeutics (NASDAQ: AXSM) investors. The biotech company's stock closed at $24.31 on Thursday, opened at $24.04 on Friday and continued to slide, falling to a low of $22.58 in the early afternoon. It's part of a longer trend for the company, which specializes in finding treatments for central nervous system disorders. As recently as Aug. 6, it was trading at $51.16.

Image source: Getty Images. 

Axsome's lead drug candidate may have hit a road bump on its way to getting approved by the Food and Drug Administration. On Aug. 9, in the company's second-quarter report, it said that the FDA had found deficiencies with the New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder.

Continue reading


Source Fool.com

Like: 0
Share

Comments